Verastem Oncology Announces New Ramp 201 Molecular Profiling And External Control Arm Analyses Describing Outcomes For Avutometinib Plus Defactinib In Recurrent Low-Grade Serous Ovarian Cancer To Be Presented At Igcs 2026

By Reuters News

Oct 2 (Reuters) - Verastem Inc VSTM.O:

  • VERASTEM ONCOLOGY ANNOUNCES NEW RAMP 201 MOLECULAR PROFILING AND EXTERNAL CONTROL ARM ANALYSES DESCRIBING OUTCOMES FOR AVUTOMETINIB PLUS DEFACTINIB IN RECURRENT LOW-GRADE SEROUS OVARIAN CANCER TO BE PRESENTED AT IGCS 2026

  • VERASTEM - AVUTOMETINIB PLUS DEFACTINIB ACHIEVES 18% ORR, 13 MONTHS MEDIAN PFS IN TRIPLE WILD-TYPE LGSOC

  • VERASTEM - AVUTOMETINIB PLUS DEFACTINIB ACHIEVES 44% ORR, 94% DISEASE CONTROL RATE IN JAPANESE LGSOC STUDY

  • VERASTEM - AVUTOMETINIB PLUS DEFACTINIB SHOWS HIGHER ORR AND PFS VERSUS CONVENTIONAL CARE IN LGSOC

Further company coverage: VSTM.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.